Research
Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to GLP-1 receptor agonists.
Tirzepatide is a newer injection that works on two hormones to lower blood sugar and lose more weight than older GLP-1 drugs.
StrongSupportsVERY_HIGH confidence
Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists.
Why this rating
Supported by the SURPASS clinical trial program.
Source
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong et al. · The Kaohsiung Journal of Medical Sciences · 2024
DOI 10.1002/kjm2.12800
narrative_reviewCited 49×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce the risk of heart failure, cardiovascular events, and renal progression in patients with type 2 diabetes, independent of glycemic control.Strong
- GLP-1 receptor agonists improve glycemic control, promote significant weight loss, and reduce cardiovascular events in patients with type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →